Investor Update – Q1 FY23 Test Volumes Rise 32% YOY

Pacific Edge today announces continuing strong growth in volumes through its laboratories of its market-leading genomic biomarker Cxbladder tests.

In the three months to the end of June 2022 Pacific Edge processed 7,055 tests up 13% on the 6,242 tests in the three months to the end of March 2022. The June 2022 figure also represents a 32% increase on the 5,356 tests processed in the same quarter of the prior financial year.

The throughput figures are disclosed in the company’s June 2022 quarterly Investor Update alongside historical quarterly test volumes starting from the first quarter of the 2021 financial year. These figures show the company has delivered a compound annual growth in test volumes since 2021 of 54%.

Pacific Edge intends to report these figures to the NZX and ASX as soon as practicable after the end of each quarter, while continuing to deliver a comprehensive data set with its full and half year results in May and November of each year.

Further detail on test volumes is covered in the Investor Update.

View the Update